Consolidated Portfolio Review Corp »

Fs Global Cr Opportunitie Fda shares owned by Consolidated Portfolio Review Corp

Quarter-by-quarter ownership of Fs Global Cr Opportunitie Fda (FSCO) shares owned by Consolidated Portfolio Review Corp from 13F filings

Historical chart of Consolidated Portfolio Review Corp investment in Fs Global Cr Opportunitie Fda

Tip: Access up to 7 years of quarterly data

All positions including Fs Global Cr Opportunitie Fda held by Consolidated Portfolio Review Corp consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Fs Global Cr Opportunitie Fda by Consolidated Portfolio Review Corp

Quarter filed Position value Share count Share price at filing
2024-03-31 $165k 28k 5.93
2023-09-30 $73k 13k 5.42
2023-06-30 $64k 13k 4.75
2023-03-31 $45k 10k 4.44

More positions owned by Consolidated Portfolio Review Corp

Vanguard Bd Index Fds Intermed Term (BIV)
Ishares Tr Rus 1000 Grw Etf (IWF)
Vanguard Index Fds Growth Etf (VUG)
Vanguard World Health Car Etf (VHT)
Microsoft Corporation (MSFT)
Goldman Sachs Etf Tr Equal Weight Us (GSEW)
Vanguard Index Fds Value Etf (VTV)
Vanguard Tax-managed Fds Van Ftse Dev Mkt (VEA)
Apple (AAPL)
Invesco Exchange Traded Fd T S&p 500 Top 50 (XLG)
Vanguard World Consum Stp Etf (VDC)
First Tr Exchange-traded Risng Divd Achiv (RDVY)
Amazon (AMZN)
Vanguard Intl Equity Index F Ftse Emr Mkt Etf (VWO)
NVIDIA Corporation (NVDA)

View all positions for Consolidated Portfolio Review Corp

Top funds holding Fs Global Cr Opportunitie Fda

Commonwealth Equity Services
Nomura Holdings
Cambridge Investment Research Advisors
Thomas J. Herzfeld Advisors
Sit Investment Associates
Wagner Wealth Management
Cetera Investment Advisers
LPL Financial
Penserra Capital Management
Envestnet Asset Management
H D Vest Advisory Services
Advisor Group Holdings
Rockefeller Capital Management
Saba Capital Management
Morgan Stanley

View all funds holding Fs Global Cr Opportunitie Fda